Aasha Harish MD, MPH
Aasha Harish
MD, MPH
Clinical Assistant Professor of Medicine
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Allergy and Immunology
Contact Information
Patient Care
Patient Care
This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.
View this physician on UBMDEducation and Training:
- Fellowship, Allergy and Immunology, University at Buffalo, Jacob School of Medicine (2017)
- Residency, Internal Medicine, University at Buffalo, Jacob School of Medicine (2015)
- MD, St. George's University (2012)
- MPH, Chronic Disease Epidemiology, Yale University (2005)
- BS, Nutritional Sciences, Cornell University (2003)
Employment:
- Assistant Professor of Medicine, Medicine, University at Buffalo, Jacob School of Medicine
Awards and Honors:
- AAAAI Faculty Development (2021)
- Early Career Leadership Development Seminar (2019)
- Gold Humanism Honor Society (2017)
- Top Doctor 2023
- Top Doctor 2022
- Top Doctor 2021
- Top Doctor 2020
Journal Articles:
- Harish A, Schwartz SA. (2020) Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions. Clinical reviews in allergy & immunology (Oct), 59(2): 231-247.
- Baptist, Ogbogu, Freigeh, Capellari, Nyenhuis, bukstein, Louisias, Nanda, Singla, Rodriquez. (1900) PRISMA. (Jan)
Abstracts:
- B Prassana Kumar and Aasha Harish. (2023) OCRELIZUMAB EXPOSURE IN FIRST TRIMESTER OF PREGNANCY WITH REASSURING INFANT B-CELL OUTCOME. Annals of Allergy, Asthma and Immunology, ACAAI 2023. San Antonio, Texas (Nov) S166 Poster
- Benipal J, Harish A. (2021) Mepolizumab: A steroid alternative for chronic eosinophilic pneumonia. Annals of allergy, asthma, and immunology, ACAAI. New Orleans, Louisiana (Nov) S87, (M122) Poster
- Harish A, Brady S. (2017) Severe Anaphylaxis to Triamcinolone. Annals of Allergy, Asthma, and Immunology, ACAAI. Boston, Massachusetts (Oct) S25, (P026) Poster
- Harish A, Dao A, Sands M. (2015) Loss of Anaphylaxis protection in inmunotherapy after discontinuation of omalizumab. Annals of Allergy, asthma, and immunology, ACAAI. San Antonio, Texas (Nov) A89, (P174) Poster
Professional Memberships:
- AAAAI
- ACAAI
- ACP
Presentations:
- "Secondary Primary Immunodeficiency" Catholic Health Grand Rounds (2023)
- "2020 Updated Guidelines for Asthma Management" UB Internal Medicine Grand Rounds (2022)
- "2020 Updated National Guidelines" Grand rounds at Catholic Health (2021)
- "Management of Severe Asthma" Primary Care Conference (2018)
Service Activities:
- UBMD Internal Medicine Board of Director; UBMD Internal Medicine Board of Director (2024–present)
- Health informatics, technology and education committee; AAAA interest section Committee member (2022–present)
- Vetrans Health Administration Committee; AAAAI Interest section committee (2022–present)
- Anaphylaxis committee; AAAAI interest section committee member (2022–present)
- Asthma and allergic diseases in older adults; AAAAI interest section committee member (2022–present)
- Womens Health Committee; AAAAI Intrest section Committee (2022–present)
- DEI committee; AAAAI intrest section committee (2022–present)
- Pediatric representative; Faculty Council for the school of medicine, University at Buffalo (2021–2022)
- UB Faculty council, school of medicine (2021–present)